112 related articles for article (PubMed ID: 20347505)
1. Tissue and serum EGFR as prognostic factors in malignant pleural mesothelioma.
Gaafar R; Bahnassy A; Abdelsalam I; Kamel MM; Helal A; Abdel-Hamid A; Eldin NA; Mokhtar N
Lung Cancer; 2010 Oct; 70(1):43-50. PubMed ID: 20347505
[TBL] [Abstract][Full Text] [Related]
2. Epidermal growth factor receptor overexpression in malignant pleural mesothelioma: prognostic correlations.
Rena O; Boldorini LR; Gaudino E; Casadio C
J Surg Oncol; 2011 Nov; 104(6):701-5. PubMed ID: 21437912
[TBL] [Abstract][Full Text] [Related]
3. Novel and existing mutations in the tyrosine kinase domain of the epidermal growth factor receptor are predictors of optimal resectability in malignant peritoneal mesothelioma.
Foster JM; Gatalica Z; Lilleberg S; Haynatzki G; Loggie BW
Ann Surg Oncol; 2009 Jan; 16(1):152-8. PubMed ID: 18998063
[TBL] [Abstract][Full Text] [Related]
4. EGFR and PDGFR differentially promote growth in malignant epithelioid mesothelioma of short and long term survivors.
Kothmaier H; Quehenberger F; Halbwedl I; Morbini P; Demirag F; Zeren H; Comin CE; Murer B; Cagle PT; Attanoos R; Gibbs AR; Galateau-Salle F; Popper HH
Thorax; 2008 Apr; 63(4):345-51. PubMed ID: 18086752
[TBL] [Abstract][Full Text] [Related]
5. Establishment of three novel human malignant pleural mesothelioma cell lines: morphological and cytogenetical studies and EGFR mutation status.
Kobayashi M; Takeuchi T; Ohtsuki Y
Anticancer Res; 2008; 28(1A):197-208. PubMed ID: 18383846
[TBL] [Abstract][Full Text] [Related]
6. Farnesyltransferase inhibitors and human malignant pleural mesothelioma: a first-step comparative translational study.
Cesario A; Catassi A; Festi L; Imperatori A; Pericelli A; Galetta D; Margaritora S; Porziella V; Cardaci V; Granone P; Dominioni L; Russo P
Clin Cancer Res; 2005 Mar; 11(5):2026-37. PubMed ID: 15756029
[TBL] [Abstract][Full Text] [Related]
7. EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinico-pathological correlations.
Destro A; Ceresoli GL; Falleni M; Zucali PA; Morenghi E; Bianchi P; Pellegrini C; Cordani N; Vaira V; Alloisio M; Rizzi A; Bosari S; Roncalli M
Lung Cancer; 2006 Feb; 51(2):207-15. PubMed ID: 16384623
[TBL] [Abstract][Full Text] [Related]
8. Is serum thioredoxin-1 a useful clinical marker for malignant pleural mesothelioma?
Maeda R; Tabata C; Tabata R; Eguchi R; Fujimori Y; Nakano T
Antioxid Redox Signal; 2011 Aug; 15(3):685-9. PubMed ID: 21375472
[TBL] [Abstract][Full Text] [Related]
9. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.
Pass HI; Wali A; Tang N; Ivanova A; Ivanov S; Harbut M; Carbone M; Allard J
Ann Thorac Surg; 2008 Jan; 85(1):265-72; discussion 272. PubMed ID: 18154821
[TBL] [Abstract][Full Text] [Related]
10. Reactivity of integrin-linked kinase in human mesothelial cell proliferation.
Watzka SB; Setinek U; Huber M; Cantonati H; Lax F; Watson S; Weigel G; Müller MR
Interact Cardiovasc Thorac Surg; 2008 Feb; 7(1):107-10. PubMed ID: 18048409
[TBL] [Abstract][Full Text] [Related]
11. Receptor tyrosine kinase and downstream signalling analysis in diffuse malignant peritoneal mesothelioma.
Perrone F; Jocollè G; Pennati M; Deraco M; Baratti D; Brich S; Orsenigo M; Tarantino E; De Marco C; Bertan C; Cabras A; Bertulli R; Pierotti MA; Zaffaroni N; Pilotti S
Eur J Cancer; 2010 Oct; 46(15):2837-48. PubMed ID: 20692828
[TBL] [Abstract][Full Text] [Related]
12. Molecular prognostic markers in malignant mesothelioma.
Kumar P; Kratzke RA
Lung Cancer; 2005 Jul; 49 Suppl 1():S53-60. PubMed ID: 15950802
[TBL] [Abstract][Full Text] [Related]
13. Thrombospondin-1 expression and clinical implications in malignant pleural mesothelioma.
Ohta Y; Shridhar V; Kalemkerian GP; Bright RK; Watanabe Y; Pass HI
Cancer; 1999 Jun; 85(12):2570-6. PubMed ID: 10375104
[TBL] [Abstract][Full Text] [Related]
14. A comparison of epidermal growth factor receptor expression in malignant peritoneal and pleural mesothelioma.
Enomoto Y; Kasai T; Takeda M; Takano M; Morita K; Kadota E; Iizuka N; Maruyama H; Haratake J; Kojima Y; Ikeda N; Nonomura A
Pathol Int; 2012 Apr; 62(4):226-31. PubMed ID: 22449226
[TBL] [Abstract][Full Text] [Related]
15. EGFR expression: associations with outcome and clinicopathological variables in malignant pleural mesothelioma.
Edwards JG; Swinson DE; Jones JL; Waller DA; O'Byrne KJ
Lung Cancer; 2006 Dec; 54(3):399-407. PubMed ID: 17049671
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor mutations in malignant pleural and peritoneal mesothelioma.
Enomoto Y; Kasai T; Takeda M; Takano M; Morita K; Kadota E; Iizuka N; Maruyama H; Haratake J; Kojima Y; Ikeda N; Inatsugi N; Nonomura A
J Clin Pathol; 2012 Jun; 65(6):522-7. PubMed ID: 22412050
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of Bax and Fas ligand in erionite and asbestos induced Turkish malignant pleural mesothelioma.
Kokturk N; Firat P; Akay H; Kadilar C; Ozturk C; Zorlu F; Gungen Y; Emri S
Lung Cancer; 2005 Nov; 50(2):189-98. PubMed ID: 16043260
[TBL] [Abstract][Full Text] [Related]
18. Aberrant expression of cell cycle regulatory genes predicts overall and disease free survival in malignant pleural mesothelioma patients.
Bahnassy AA; Zekri AR; Abou-Bakr AA; El-Deftar MM; El-Bastawisy A; Sakr MA; El-Sherif GM; Gaafar RM
Exp Mol Pathol; 2012 Aug; 93(1):154-61. PubMed ID: 22504106
[TBL] [Abstract][Full Text] [Related]
19. Clinico-pathological and biological prognostic factors in pleural malignant mesothelioma.
O'Byrne KJ; Edwards JG; Waller DA
Lung Cancer; 2004 Aug; 45 Suppl 1():S45-8. PubMed ID: 15261433
[TBL] [Abstract][Full Text] [Related]
20. Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells.
Kawaguchi K; Murakami H; Taniguchi T; Fujii M; Kawata S; Fukui T; Kondo Y; Osada H; Usami N; Yokoi K; Ueda Y; Yatabe Y; Ito M; Horio Y; Hida T; Sekido Y
Carcinogenesis; 2009 Jul; 30(7):1097-105. PubMed ID: 19380521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
